TALEN

TALEN1-pkd1a

ID
ZDB-TALEN-170524-1
Name
TALEN1-pkd1a
Previous Names
None
Target
Target Sequence 1
5' - TACCACAACCACAGGCAG - 3'
Target Sequence 2
5' - TGCCCTGCCGAAGCAC - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
zf1067 pkd1a
zf1068 pkd1a
Expression
Gene expression in Wild Types + TALEN1-pkd1a
No data available
Phenotype
Phenotype resulting from TALEN1-pkd1a
No data available
Phenotype of all Fish created by or utilizing TALEN1-pkd1a
Phenotype Fish Conditions Figures
pronephric duct cystic, ameliorated pkd1azf1067/zf1067 chemical treatment by environment: carbamazepine, chemical treatment by environment: sirolimus Fig. 6 from Zhu et al., 2017
pronephric duct has fewer parts of type pronephric duct autophagosome, abnormal pkd1azf1067/zf1067 chemical treatment by environment: bafilomycin A1 Fig. 2 from Zhu et al., 2017
pronephros renal filtration occurrence, ameliorated pkd1azf1067/zf1067 chemical treatment by environment: bafilomycin A1 Fig. 6 from Zhu et al., 2017
pronephros renal filtration occurrence, ameliorated pkd1azf1067/zf1067 chemical treatment by environment: sirolimus Fig. 6 from Zhu et al., 2017
pronephros renal filtration decreased occurrence, abnormal pkd1azf1067/zf1067 control Fig. 1Fig. 6 from Zhu et al., 2017
pronephros development decreased process quality, abnormal pkd1azf1067/zf1067 standard conditions Fig. 1Fig. 4 from Zhu et al., 2017
pronephric duct cystic, ameliorated pkd1azf1067/zf1067 chemical treatment by environment: sirolimus Fig. 6 from Zhu et al., 2017
heart edematous, abnormal pkd1azf1067/zf1067 standard conditions Fig. 1 from Zhu et al., 2017
TOR signaling increased occurrence, abnormal pkd1azf1067/zf1067 standard conditions Fig. 2 from Zhu et al., 2017
pronephros renal filtration occurrence, ameliorated pkd1azf1067/zf1067 chemical treatment by environment: minoxidil Fig. 6 from Zhu et al., 2017
pronephric tubule dilated, abnormal pkd1azf1067/zf1067 standard conditions Fig. 1 from Zhu et al., 2017
pronephric duct cystic, ameliorated pkd1azf1067/zf1067 chemical treatment by environment: bafilomycin A1 Fig. 6 from Zhu et al., 2017
pronephric duct regulation of autophagy process quality, abnormal pkd1azf1067/zf1067 standard conditions Fig. 2 from Zhu et al., 2017
pronephric duct cystic, ameliorated pkd1azf1067/zf1067 chemical treatment by environment: carbamazepine Fig. 6 from Zhu et al., 2017
whole organism Ab6-mtor labeling increased amount, abnormal pkd1azf1067/zf1067 standard conditions Fig. 2 from Zhu et al., 2017
pronephric duct cystic, abnormal pkd1azf1067/zf1067 control Fig. 1Fig. 6 from Zhu et al., 2017
pronephros renal filtration occurrence, ameliorated pkd1azf1067/zf1067 chemical treatment by environment: carbamazepine Fig. 6 from Zhu et al., 2017
pronephric duct autophagy decreased occurrence, abnormal pkd1azf1067/zf1067 chemical treatment by environment: bafilomycin A1 Fig. 2 from Zhu et al., 2017
pronephric duct cystic, ameliorated pkd1azf1067/zf1067 chemical treatment by environment: minoxidil Fig. 6 from Zhu et al., 2017
pronephros development decreased process quality, abnormal pkd1azf1067/zf1067 + MO4-atg5 standard conditions Fig. 4 from Zhu et al., 2017
pronephric duct cystic, exacerbated pkd1azf1067/zf1067 + MO4-atg5 standard conditions Fig. 4 from Zhu et al., 2017
pronephros development decreased process quality, abnormal pkd1azf1067/zf1067; pkd1bzf1070/zf1070 standard conditions Fig. 1 from Zhu et al., 2017
pronephros development decreased process quality, exacerbated pkd1azf1067/zf1067; pkd1bzf1070/zf1070 standard conditions Fig. 1 from Zhu et al., 2017
pronephric duct cystic, exacerbated pkd1azf1067/zf1067; pkd1bzf1070/zf1070 standard conditions Fig. 1 from Zhu et al., 2017
pronephric duct cystic, abnormal pkd1azf1067/zf1067; pkd1bzf1070/zf1070 standard conditions Fig. 1 from Zhu et al., 2017
Citations